Diagnosis and Management of Rare Case of Locally Advanced Non-Clear Renal-Cell Carcinoma: A Case Report
Marwa Jabbar Hussein1 and Faraed Dawood Salman2*
1Mosul University-College of Medicine, FKBMS-Medical Oncology/Erbil-Iraq, ESMO/ASCO certified, Iraq
2Professor in Dental Assistant Department/Medical Technical Institute, Erbil Polytechnic University, Erbil, Iraq
*Corresponding Author: Faraed Dawood Salman, Professor in Dental Assistant Department/Medical Technical Institute, Erbil Polytechnic University, Erbil, Iraq.
Received: August 11, 2023;
Published: August 17, 2023
Introduction: Non-clear cell renal carcinoma is one of the rarest malignancy subtypes in RCC (Renal Cell Carcinoma), with no specialized treatment. In this case report, the chemotherapeutic drugs carboplatin and paclitaxel were reviewed and studied for the treatment of a rare tumor that was high grade, poorly differentiated, unclassified non-clear renal cell carcinoma (RCC) of locally advanced stage with active disease post-operatively.
A 23-years-old woman was diagnosed with locally advanced, high grade, poorly differentiated, unclassified non-clear renal cell carcinoma (RCC) with difficulty, and this case report will discuss chemotherapy treatment options in non-clear RCC locally advanced (stage III) with the use of carboplatin and paclitaxel for 6 cycles every 21 days and its role and impact on tumor response, general clinical condition, and prognosis.
Results: After receiving 6 cycles of chemotherapy (carboplatin and paclitaxel) as adjuvant therapy following total radical left nephrectomy for this patient with locally advanced unclassified undifferentiated Non-Clear RCC and active pelvic lymph node metastases post-operatively, there was complete disease response with a total absence for this active lymph node by follow-up PET scan. The patient in addition had a dramatic clinical response, going 3 years without any evidence of disease recurrence.
Conclusion: Patients with unusual displays of locally advanced, unclassified, poorly differentiated Non-Clear Renal Cell Carcinoma (nccRCC) after radical nephrectomy had complete tumor responses to chemotherapy carboplatin and paclitaxel as adjuvant treatment for 6 cycles with reduced toxicity profiles, indicating that this treatment option can be used for this highly unusual tumor type.
Keywords: nccRCC (Non-clear renal cell carcinoma); IHC (Immune Histochemistry); MRI (Magnetic Resonant Imaging); PET scan (Positron Emission Tomography)
- Rini BI., et al. “Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal Cell-Carcinoma”. The New England Journal of Medicine 12 (2019): 1116-1127.
- Motzer RJ. “Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma”. The New England Journal of Medicine (2018).
- Mahoney KM., et al. “Phase 2 study of Bevacizumab and Temsirolimus After VEGR in metastatic Renal Cell Carcinoma”. Clinical Genitourinary Cancer 4 (2016): 304-313.e6.
- Siegel RL., et al. “Cancer statistics, 2020”. CA: A Cancer Journal for Clinicians 70 (2020): 7-30.
- Fernandez-Pello S., et al. “A systematic Review and metanalysis comparing the effectiveness and adverse effects of different systemic treatments for Non-Clear Cell Renal Cell Carcinoma”. European Urology 71 (2017): 426-436.
- Moch H., et al. “WHO classification of tumors of the urinary system, and male genital organs-Part A: Renal, Penile, and Testicular Tumors”. European Urology 70 (2016): 93-105.
- Bylow KA., et al. “Phase III trial of carboplatin and paclitaxel in papillary renal cell carcinoma”. Clinical Genitourinary Cancer 1 (2009): 39-42.
- Tsimafeyeu I., et al. “Phase III multicenter, uncontrolled trial of single agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma”. American Journal of Clinical Oncology Cancer Clinical Trials 35.3 (2012): 251-25
- Gore ME., et al. “Final results from the large sunitinib global expanded-accesstrial in metastatic renal cell carcinoma”. British Journal of Cancer 1 (2015): 12-19.
- Lee JL., et al. “Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma”. Annals of Oncology 8 (2012): 2018-2114.
- Molina AM., et al. “Phase II trial of sunitinib in patients with metastatic non clear cell renal cell carcinoma”. Investigational New Drugs 1 (2012): 335-340.
- Tannir NM., et al. “A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma”. European Urology 6 (2012): 1013-1019.
- Park I., et al. “A multicenter phase II trial of Axitinib in patients with recurrent of metastatic Non-Clear Renal Cell Carcinoma Who Had Failed Prior Treatment with Temsirolimus”. Clinical Genitourinary Cancer 5 (2018): e997-1002.
- Jung KS., et al. “Pazopanib for the treatment of Non-Clear Renal Cell Carcinoma A Single-Arm, Open-Label, Multi-Center, Phase II study”. Cancer Research and Treatment 2 (2018): 488-494.
- Koh Y., et al. “Phase II trial of everolimus for the treatment of non-clear cell renal cell carcinoma”. Annals of Oncology4 (2013): 1026-1031.
- Liu K., et al. “Papillary renal cell carcinoma: A clinicopathological and whole-Genome Exone Sequencing Study”. International Journal of Clinical and Experimental Pathology 8 (2015): 8333-8335.
- Nickerson ML., et al. “Mutations in a novel gene lead to kidney tumors, lung wall defects and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome”. Cancer Cell 2 (2002): 157-164.
- Mennitto A., et al. “Management collecting duct carcinoma: An Encouraging Result in a patient treated with cabozantinib”. Clinical Genitourinary Cancer 16 (2018): e521-e523.
- McDermott DF., et al. “Checkmate 214 post-hoc analysis of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features”. JCO 37 (2019): 4513.
- Tannir NM., et al. “Overall survival and independent review of response in checkmate 214 with 42 month follow-up: first-line Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) in patients with advanced renal cell carcinoma (ARCC)”. JCO 38 (2020): 609.
- Malouf GG., et al. “Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the juvenile RCC network”. Annals of Oncology 21 (2010): 1834-1838.
- Tannir NM., et al. “Everolimus versus sunitnib prospective evaluation in metastatic Non-Clear Cell Renal Carcinoma (ESPN): A randomized multicenter phase 2 trial”. European Urology 69 (2016): 866-874.
- Armstrong AJ., et al. “Everolimus versus sunitinib for patients with metastatic non-clear renal cell carcinoma (ASPEN): A multicenter, open-label, randomized phase 2 trial”. Lancet Oncology 17 (2016): 378-388.
- Gore ME., et al. “Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded access trial”. Lancet Oncology 10 (2019): 757-763.
- Bratslavsky G., et al. “Pseudo hypoxic pathways in renal cell carcinoma”. Clinical Cancer Research 13 (2007): 4667-4671.
- Rini BI and Campbell SC. “The evolving role of surgery for advanced renal cell carcinoma in the area of molecular targeted therapy”. Journal of Urology 177 (2007): 1978-1984.
- Rini BI. “VEGF-targeted therapy in metastatic renal cell carcinoma”. Oncologist 10 (2015): 191-197.
- Abel EJ and Wood CG. “Cytoreductive nephrectomy for metastatic RCC in the area of targeted therapy”. Nature Reviews Urology 6 (2009): 375-383.